18678-94-9

Upstream product

• 82002-21-9 2-O-Benzyl-1-O-hexadecyl-3-O-trityl-glycerin 
• 96924-82-2 Benzoic acid 2-benzyloxy-3-hexadecyloxy-propyl ester 
• 82002-20-8 1-O-hexadecyl-3-O-trityl-rac-glycerol 
• 89496-73-1 4-(n-hexadecyloxymethyl)-2,2-dimethyl-1,3-dioxolane 
• 112-82-3 hexadecanyl bromide 
• 1233733-83-9 C₃₂H₆₀O₃Si 
• 100-44-7 benzyl chloride 
• 137618-68-9 Benzoic acid 2-benzyloxy-3-hydroxy-propyl ester 
• 14690-00-7 2-O-benzylglycerol 
• 36653-82-4 1-Hexadecanol 
• 68728-34-7 5-benzyloxy-2-phenyl-1,3-dioxane 
• 117606-92-5 cetyl glycidyl ether 
• 18371-73-8 1-chloro-3-hexadecylhydroxy-2-propanol 
• 6145-69-3 3-(hexadecyloxy)-1,2-propanediol 

Downstream Products

• 82002-26-4 Acetic acid (2R,3S,4S,5R,6R)-3,5-diacetoxy-2-acetoxymethyl-6-(2-benzyloxy-3-hexadecyloxy-propoxy)-tetrahydro-pyran-4-yl ester 
• 78119-19-4 2-hydroxy-3-(hexadecyloxy)-propyl 2-trimethylammonioethyl phosphate 
• 18678-98-3 Rac_. 1-O-Hexadecyl-2-O-benzylglycero-3-phosphocholin 
• 118985-48-1 2-benzyloxy-3-hexadecyloxypropyl 1-methyl-1-azoniabicyclo[2,2,2]-3-octyl phosphate 
• 118469-66-2 2-bromo-1-methylethylphosphoric acid 3-(hexadecyloxy)-2-(phenylmethoxy)propyl ester 
• 104478-43-5 2-(Benzyloxy)-3-(hexadecyloxy)propyl 3-trimethylammoniopropyl phosphate 
• 92948-61-3 2-O-benzyl-1-O-hexadecyl-3-O-mesylglycerol 
• 1233733-89-5 C₃₅H₆₂NO₆⁽¹⁺⁾ 
• 96924-86-6 C₂₈H₄₉BrO₆P^(1-)*Na⁽¹⁺⁾ 
• 97150-24-8 4-hydroxy-N,N,N,6-tetramethyl-7-(phenylmethoxy)-3,5,9-trioxa-4-phosphapentacosan-1-aminium 4-oxide, hydroxide 
• 123342-71-2 4-(hexadecyloxy)-3-(phenylmethoxy)-2-butanol 
• 98899-66-2 2-O-Benzyl-1-O-hexadecylglyceryl-3-(2-trimethylammonioethyl-phosphonat) 
• 99884-84-1 C₃₉H₇₄NO₆P 
• 99884-83-0 C₃₇H₇₀NO₆P 

Relevant academic research and scientific papers

Design, synthesis and cytotoxicity of chimeric erlotinib-alkylphospholipid hybrids

Two series of erlotinib-alkylphospholipid hybrids were prepared and evaluated for their antiproliferative activities against a panel of four cell lines representing lung, breast, liver and skin cancers using erlotinib and miltefosine as reference standards. Amide analogs elicited more enhanced cytotoxic activity than analogous esters. Amide derivatives 8d and 8e exhibited promising broad-spectrum antiproliferative activity and higher efficacy than reference erlotinib and miltefosine. Their cellular GI50 values was in the ranges of 24.7–46.9 μM and 26.8–43.1 μM for 8e and 8d respectively. Assay results of the inhibitory activity of the prepared compounds on EGFR kinase reaction and Akt phosphorylation in conjugation with statistical correlation analysis indicated that other mechanisms might contribute to their elicited cytotoxicities. In addition, statistical correlation analysis revealed that mechanisms of elicited cytotoxicities for amide series might be different from ester series. In addition, correlation analysis indicated variations in the mechanisms according to the types of cell line.

PLASMALOGEN COMPOUNDS, PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AND METHODS FOR TREATING DISEASES OF THE AGING

Described herein are routes of synthesis and therapeutic uses of 1-alkyl, 2-acyl glycerol derivatives of formula I: which when administered to mammalian biological systems result in increased cellular concentrations of specific sn-2 substituted ethanolamine plasmalogens independent of the ether lipid synthesis capacity of the system. Elevating levels of the specific sn-2 substituted species in this way can cause lowering of membrane cholesterol levels and the lowering of amyloid secretion. These compounds can be used for the treatment or prevention of diseases of aging associated with increased membrane cholesterol, increased amyloid, and decreased plasmalogen levels, such as neurodegeneration (including Alzheimer''s disease, Parkinson''s disease and age-related macular degeneration), cognitive impairment, dementia, cancer (e.g. prostate, lung, breast, ovarian, and kidney cancers), osteoporosis, bipolar disorder and vascular diseases (such as atherosclerosis, hypercholesterolemia).

Influence of α-branched fatty acid chains on the thermotropic behaviour of racemic 1-O-hexadecyl-2-acyl-glycero-3-phosphocholines

Phosphatidylcholines containing an α-branched palmitic acid ester linked to position C2 of the glycerol backbone were synthesized and characterized using differential scanning calorimetry and X-ray diffraction. As the length of the sidegroup substituted on the palmitic acid chain is changed, the calorimetric parameters pass through a minimum. The polymorphic behaviour is different when the sidegroup is larger, or smaller, than propyl. The comparison of the physicochemical parameters of isomers differing in the bonding of the branched chain fatty acid to the glycerol backbone (to position C1 or C2, respectively) shows that the chains are nonequivalent. Keywords: Phosphatidylcholine; Branched chain fatty acids; Microcalorimetry; X-ray diffraction; Polymorphism

Antihypertensive phosphate derivatives

Antihypertensive phosphate derivatives having the following formula are described: STR1 wherein X is a C1 -C24 branched or straight chain alkyl group; R is selected from the group consisting of hydrogen and C1 -C4 alkyl, with the proviso that at least one R group is not hydrogen; T is selected from the group consisting of hydrogen and STR2 wherein R1 is selected from the group consisting of hydrogen, C1 -C4 branched or straight chain alkyl, C1 -C4 branched or straight chain alkoxy and C1 -C4 branched or straight chain alkylamino; Q is a bivalent radical selected from the group consisting of --(CH2)p -- and --(CHR1)p --, wherein p is an integer from 2 to 12 and the moiety --(CHR1)p -- represents an alkylene chain which is substituted by one or more C1 -C10 alkyl groups or phenyl groups; Z is selected from the group consisting of STR3 wherein R2 may be chain alkyl and q is an integer from 4 to 7; in either the racemic or in the optically active form.

Structure-Activity Relationship in PAF-acether. 3. Hydrophobic Contribution to Agonistic Activity

The synthesis of some selected PAF-acether homologues with an alkoxy-chain length from C1 to C20 in position 1 is described.All agonist activities are closely correlated among themselves and with the calculated fatty-chain hydrophobicity.After a discussio

Phosphocholine derivatives having antihypertensive action

Phosphocholine derivatives and compositions are described which are useful as hypotensive agents and in the treatment of hypertension in warm-blooded animals.

Facile synthesis of platelet-activating factor and racemic analogues containing unsaturation in the sn-1-alkyl chain

Platelet-activating factor, (PAF, 1-O-hexadecyl-2-acetyl-sn-glycero-3-phophocholine), and octadecyl-PAF were synthesized chemically as the racemates. The sn-1-O-alkyl isomers were isolated after treatment of the racemates with phospholipase A2 and subsequent reacetylation of the 1-O-alkyl-2-lyso-sn-glycero-3-phosphocholines released. Analogues of PAF containing unsaturated alkyl moieties at the sn-1 position were synthesized by utilizing the methoxyethoxymethyl protecting group as a novel method for preparing unsaturated alkyl lipids. This procedure provides a facile means for preparing unsaturated ether phospholipids of defined structure that may be tritiated to high radiospecific activity for metabolic studies. Unsaturation in the alkyl chain had minimal effect on the bioactivities examined in this study.